Immune checkpoint blockade with anti-CTLA-4 and anti-PD1 antibodies has shown promising results in HCC, but some HCC patients developed resistance to immune checkpoint inhibitors by upregulating IDO1. The gene discussed is IDO1; the disease is hepatocellular carcinoma.